<DOC>
	<DOCNO>NCT00085696</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness VELCADE give combination rituximab patient Relapsed Refractory Indolent B-Cell Lymphoma . This study investigate treatment VELCADE rituximab increase time take lymphoma get worse .</brief_summary>
	<brief_title>VELCADE® ( Bortezomib ) With Rituximab Subjects With Relapsed Refractory Indolent B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Male female subject 18 year old Diagnosis Bcell lymphoma ( CD20+ ) follicular lymphoma ( grades 1 , 2 , 3 ) marginal zone lymphoma ( extranodal , nodal , splenic ) Documented relapse progression follow prior antineoplastic treatment . At least 1 measurable lymph node mass &gt; 1.5 cm . No active CNS lymphoma Voluntary consent Previous treatment VELCADE Any antineoplastic experimental therapy within 3 week first dose study drug . Any treatment nitrosoureas within 6 week first dose study drug . Treatment Zevalin™ Bexxar® within 10 week first dose study drug . Rituximab , Campath® unconjugated therapeutic antibody within 4 week first dose study drug . Radiation therapy within 3 week first dose study drug . Major surgery within 2 week first dose study drug . Peripheral neuropathy neuropathic pain History allergic reaction attributable compound contain boron mannitol Known anaphylaxis hypersensitivity component rituximab Diagnosed treat select malignancy NHL within 5 year . Active systemic infection require treatment Female subject must pregnant , breastfeeding , become pregnant course study . Male subject agree use acceptable method contraception duration study Any serious medical psychiatric illness likely interfere participation clinical study Concurrent treatment another investigational agent . Concurrent participation nontreatment study allow , interfere participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin 's</keyword>
	<keyword>NHL</keyword>
	<keyword>B-Cell</keyword>
	<keyword>Indolent</keyword>
</DOC>